In the past 5 years publicly funded research organisations have achieved AU$1.3B in commercialisation deals in Australia and NZ$671M in New Zealand. Across both countries 350 new companies have been created.
These figures from KCA’s SCOPR® 2023 Survey of Commercialisation Outcomes from Public Research show tremendous success in the commercialisation of publicly funded research, achieving positive impact in society in a wide range of technologies from life sciences through to MedTech, IT and engineering solutions.
In 2023, 70 Australian and New Zealand research organisations participated, an increase of 9% on last year.
Key achievements for 2023 include:
- 72 New Companies Created – 56 in Australia and 16 in New Zealand
- $430M+ Commercialisation Income – AU$290M in Australia and NZ$157M in New Zealand
- $1.1B+ Industry Contracts– AU$1B in Australia and NZ$136M in New Zealand
- 791 Commercial Deals – 741 in Australia and 50 in New Zealand
“The commercialisation output of the public research sector hasn’t been overly affected by the impact of Covid. In fact, the excellent results have been generated through the efforts of only 407 Research Commercialisation Staff”, said Mr John Grace AO, “It is a stellar effort supporting over 48,000 researchers in Australia and New Zealand.”
“The strong support for SCOPR® continues to demonstrate its interest to the public research sector. In our strategic alliance with the Department of Education they see the data as being very important in their policy decision making,” KCA Chair Quin Chang said.